Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 75

1.

A comment on the question 'Are the aims of the K/DOQI guidelines for mineral metabolism disorders in stages 3-5 chronic kidney disease unachievable or inadequate?

Negri AL.

Nefrologia. 2013;33(3):424. doi: 10.3265/Nefrologia.pre2013.Apr.11941. English, Spanish. No abstract available.

2.

Response to the comment 'are the aims of the K/DOQI guidelines for mineral metabolism disorders inpatients with stage 3-5 chronic kidney disease unachievable or inadequate?

Fernández-Giráldez E.

Nefrologia. 2013;33(3):424-5. doi: 10.3265/Nefrologia.pre2013.May.12102. English, Spanish. No abstract available.

3.

Are the K/DOQI objectives for bone mineral alterations in stage 3-5 chronic kidney disease patients unreachable or inadequate?

Fernández E.

Nefrologia. 2013 Jan 18;33(1):1-6. doi: 10.3265/Nefrologia.pre2012.Dec.11890. English, Spanish. No abstract available.

4.

Characteristics of bone mineral metabolism in patients with stage 3-5 chronic kidney disease not on dialysis: results of the OSERCE study.

Górriz JL, Molina P, Bover J, Barril G, Martín-de Francisco AL, Caravaca F, Hervás J, Piñera C, Escudero V, Molinero LM; en nombre de los investigadores del estudio OSERCE.

Nefrologia. 2013 Jan 18;33(1):46-60. doi: 10.3265/Nefrologia.pre2012.Nov.11703. English, Spanish.

5.

Guidelines for disorders of mineral metabolism and secondary hyperparathyroidism should not yet be modified.

Ix JH, Quarles LD, Chertow GM.

Nat Clin Pract Nephrol. 2006 Jun;2(6):337-9.

PMID:
16932455
7.
8.

Reappraisal of 2003 NKF-K/DOQI guidelines for management of hyperparathyroidism in chronic kidney disease patients.

Monge M, Shahapuni I, Oprisiu R, El Esper N, Morinière P, Massy Z, Choukroun G, Fournier A.

Nat Clin Pract Nephrol. 2006 Jun;2(6):326-36.

PMID:
16932454
9.

Application of NKF-K/DOQI Clinical Practice Guidelines for Bone Metabolism and Disease: changes of clinical practices and their effects on outcomes and quality standards in three haemodialysis units.

Arenas MD, Alvarez-Ude F, Gil MT, Soriano A, Egea JJ, Millán I, Amoedo ML, Muray S, Carretón MA.

Nephrol Dial Transplant. 2006 Jun;21(6):1663-8. Epub 2006 Feb 7.

PMID:
16464885
10.

Interprovincial differences in the achievement of K/DOQI targets of mineral metabolism in Canada.

Lebner AC, Beard KM, Soroka SD, Cournoyer SH, Da Roza GA, Geary DF, Mendelssohn DC.

Nephrol Dial Transplant. 2011 Jan;26(1):156-63. doi: 10.1093/ndt/gfq459. Epub 2010 Jul 28.

PMID:
20667990
11.

Gene polymorphism association studies in dialysis: bone and mineral metabolism.

Erturk S; DialGene Consortium.

Semin Dial. 2006 May-Jun;19(3):232-7. Review.

PMID:
16689975
12.

Adherence to K/DOQI guidelines for calcium-based phosphate binders in clinical practice.

Shastri J, Tran A, Covit A, Pepe J, Sherman RA.

J Ren Nutr. 2008 Jul;18(4):370-4. doi: 10.1053/j.jrn.2008.04.011.

PMID:
18558302
13.

Association between C-reactive protein and biomarkers of bone and mineral metabolism in chronic hemodialysis patients: a cross-sectional study.

Lee CT, Tsai YC, Ng HY, Su Y, Lee WC, Lee LC, Chiou TT, Liao SC, Hsu KT.

J Ren Nutr. 2009 May;19(3):220-7. doi: 10.1053/j.jrn.2008.11.004. Epub 2009 Feb 24.

PMID:
19243976
14.

Scintigraphic skeletal changes in dialysis and kidney transplanted patients.

Madsen S, Olgaard K, Heerfordt J, Brix E, Vistisen L.

Adv Exp Med Biol. 1977;81:611-9. No abstract available.

PMID:
197824
15.

How to apply and adapt international guidelines on bone metabolism and disease to the management of Japanese dialysis patients.

Fukagawa M, Akizawa T.

Ther Apher Dial. 2005 Feb;9(1):1-2. No abstract available.

PMID:
15828896
16.

Bone lead and renal failure.

Jorens PG, Van de Vyver FL, Nuyts GD, Daelemans RA, D'Haese PC, Elseviers MM, De Broe ME.

Nephron. 1991;58(4):494-7. No abstract available.

PMID:
1922624
17.

Adherence to K/DOQI practice guidelines for bone metabolism and disease.

Hoy T, Fisher M, Barber B, Borker R, Stolshek B, Goodman W.

Am J Manag Care. 2007 Nov;13(11):620-5.

18.

K/DOQI guidelines for bone metabolism and disease in chronic kidney disease patients: some therapeutic implications.

Uribarri J; National Kidney Foundation.

Semin Dial. 2004 Sep-Oct;17(5):349-50.

PMID:
15461740
19.

Mineral metabolism parameters throughout chronic kidney disease stages 1-5--achievement of K/DOQI target ranges.

Craver L, Marco MP, Martínez I, Rue M, Borràs M, Martín ML, Sarró F, Valdivielso JM, Fernández E.

Nephrol Dial Transplant. 2007 Apr;22(4):1171-6. Epub 2007 Jan 5.

PMID:
17205962
20.

Effects of decreasing dialysate magnesium in patients with chronic renal failure.

Burnell JM, Teubner E.

Proc Clin Dial Transplant Forum. 1976 Nov 19-22;6:191-8. No abstract available.

PMID:
1029885

Supplemental Content

Support Center